As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/21/19  Cantabio Pharmaceuticals Inc.     15-12G      6/21/19    1:9K                                     Empire Stock Transf… Inc

Document/Exhibit                   Description                      Pages   Size 

 1: 15-12G      Form 15                                             HTML      8K 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 000-54905

 

Cantabio Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

 

2225 East Bayshore Road, Suite 200

Palo Alto, CA 94303

(844) 200-2826

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock

(Title of each class of securities covered by this Form)

 

None.

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)	[  ]
Rule 12g-4(a)(2)	[X]
Rule 12h-3(b)(1)(i)	[  ]
Rule 12h-3(b)(1)(ii)	[  ]
Rule 15d-6	[  ]
Rule 15d-22(b)	[  ]

 

Approximate number of holders of record as of the certification or notice date: 339

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Cantabio Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: June 21, 2019	CANTABIO PHARMACEUTICALS INC.
	By: /s/ Gergely Toth
	Name: Gergely Toth
	Title: Chairman of the Board, President and Chief Executive Officer